Intercellular Targets of Prostate Cancer
作者： Young E. Whang , Daniel J. George
DOI: 10.1007/978-1-59745-224-3_25
关键词:
摘要: Prostate cancer is a hormonally driven disease with relatively long natural history and predictable pattern of metastasis. Intercellular growth factor signals play an important role in the progression prostate both hormone-intact setting as well androgen deprivation therapy. Many intercellular factors have been implicated based on various levels evidence, from epidemiological studies to preclinical models. In this chapter, we review some most prominent pathways involved cancer, particular so-called hormone-refractory setting. particular, focus those for which targeted therapeutics developed are being tested clinical trials patients advanced cancer. future, insights into biology these targets may lead patient selection upon biomarker or molecular profiles order enrich reponse
springer.com
sci-hub.st 参考文章(98)
Theresa A. Guise, Khalid S. Mohammad, Endothelins in bone cancer metastases. Cancer treatment and research. ,vol. 118, pp. 197- 212 ,(2004) , 10.1007/978-1-4419-9129-4_9
P R Carroll, N Weidner, J Flax, W Blumenfeld, J Folkman, Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology. ,vol. 143, pp. 401- 409 ,(1993)
Turner T, Wells A, Souto Jc, Kassis J, Kim Hg, EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histology and Histopathology. ,vol. 14, pp. 1175- 1182 ,(1999) , 10.14670/HH-14.1175
Thelma Angeles, John Lamb, John T. Isaacs, Craig A. Dionne, Daniel J. George, Jitesh Jani, Chikara Murakata, Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Research. ,vol. 59, pp. 2395- 2401 ,(1999)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
L Claesson-Welsh, Platelet-derived growth factor receptor signals. Journal of Biological Chemistry. ,vol. 269, pp. 32023- 32026 ,(1994) , 10.1016/S0021-9258(18)31591-6
Carlos Cordon-Cardo, David Verbel, Marija Drobnjak, Howard I. Scher, Iman Osman, Michael Morris, David Agus, Jeffrey S. Ross, HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer Clinical Cancer Research. ,vol. 7, pp. 2643- 2647 ,(2001)
Noah Craft, Yuriy Shostak, Michael Carey, Charles L. Sawyers, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. ,vol. 5, pp. 280- 285 ,(1999) , 10.1038/6495
Michael Borre, Jens Overgaard, Benni Nerstrøm, Association between Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF), VEGF-expressing Neuroendocrine-differentiated Tumor Cells, and Outcome in Prostate Cancer Patients Subjected to Watchful Waiting Clinical Cancer Research. ,vol. 6, pp. 1882- 1890 ,(2000)
Jeanette M Wood, G Bold, Elizabeth Buchdunger, R Cozens, Stefano Ferrari, Jörg Frei, F Hofmann, Jürgen Mestan, H Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, A Theuer, Harry Towbin, Fritz Wenger, K Woods-Cook, A Menrad, Gerhard Siemeister, M Schirner, Karl-Heinz Thierauch, Martin R Schneider, J Drevs, G Martiny-Baron, F Totzke, Dieter Marmé, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Research. ,vol. 60, pp. 2178- 2189 ,(2000)